sugammadex as reversal drugs

PreclinicalSmall molecule

PPeking Union Medical College Hospital

sugammadex as reversal drugs is one of 3 small molecule programs targeting Neostigmine. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeostigmineUnknown status

NeostigminePreclinical

Unknown status

Competition

Competitive Landscape

2 competitors in Neostigmine

#DrugCompanyPhaseTrials

Neuromuscular Blocking Agents

UUniversity of Maryland, Baltimore

Phase 3

1 2

sugammadex as reversal drugs

PPeking Union Medical College Hospital

Preclinical

1 3

Sugammadex Sodium

KKorea University Anam Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neostigmine1 trial

Influence of Neostigmine vs. Sugammadex on PORC and PPCs by Ultrasonography

Unknown status·PPeking Union Medical College Hospital·N/A·NCT05040490·414 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for sugammadex as reversal drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sugammadex as reversal drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sugammadex as reversal drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPeking Union Medical College Hospital

sugammadex as reversal drugs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neostigmine1 trial

References

Drug Info

Quick Facts

Related News